pharma · Unstable Angina Pectoris · Gastric Carcinoma · COLL
COLLEGIUM PHARMACEUTICAL
COLLEGIUM PHARMACEUTICAL, INC
COLLEGIUM PHARMACEUTICAL clinical programs — 8 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 100 Technology Center Dr, Stoughton, Massachusetts 02072, US
- Employees
- 617
- Programs
- 29
- Drugs
- 48
- Patents
- 28
COLLEGIUM PHARMACEUTICAL projects
8 ClinicalTrials.gov programs sponsored by COLLEGIUM PHARMACEUTICAL.
COLLEGIUM PHARMACEUTICAL has 8 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Crushed ticagrelor followed by morphine
COLLEGIUM PHARMACEUTICAL, INC
Unstable Angina Pectoris
2 trials -
Levosimendan
COLLEGIUM PHARMACEUTICAL, INC
Systolic Heart Failure
1 trial -
Morphine
COLLEGIUM PHARMACEUTICAL, INC
ST-segment Elevation Myocardial Infarction
1 trial -
Pulverized ticagrelor sublingually
COLLEGIUM PHARMACEUTICAL, INC
Unstable Angina Pectoris
1 trial -
Rifaximin
COLLEGIUM PHARMACEUTICAL, INC
ACS - Acute Coronary Syndrome
1 trial -
Rosuvastatin and Ezetimibe morning or evening administration
COLLEGIUM PHARMACEUTICAL, INC
Hypercholesterolemia
1 trial -
Ticagrelor followed with Methoxyflurane
COLLEGIUM PHARMACEUTICAL, INC
Unstable Angina
1 trial -
Xtampza ER (oxycodone)
COLLEGIUM PHARMACEUTICAL, INC
Chronic Pain
1 trial
Frequently asked questions
How many clinical projects does COLLEGIUM PHARMACEUTICAL have?
8 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.